Research programme: ion channel antagonists - Xenon PharmaceuticalsAlternative Names: Ion channel inhibitors - Xenon Pharmaceuticals
Latest Information Update: 06 Oct 2016
At a glance
- Originator Xenon Pharmaceuticals
- Mechanism of Action Ion channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 31 Oct 2014 Preclinical trials in Undefined indication in USA (unspecified route)